Related Experiment Video
Updated: May 29, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from
Jean-Claude Tardif1, Eileen O'Meara, Michel Komajda
1Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montreal, Quebec, Canada H1T 1C8. jean-claude.tardif@icm-mhi.org
Ivabradine effectively reduced left ventricular remodelling in heart failure patients. This treatment improved key cardiac function metrics and was associated with better clinical outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Medical Imaging
Background:
- Heart failure (HF) with systolic dysfunction is characterized by left ventricular (LV) remodelling.
- Effective treatments targeting LV remodelling are crucial for improving outcomes in HF patients.
Purpose of the Study:
- To evaluate the impact of ivabradine on left ventricular remodelling in patients with chronic heart failure.
- To assess the effects of ivabradine on LV end-diastolic volume index and LV ejection fraction.
Main Methods:
- The SHIFT echocardiographic substudy enrolled patients with chronic HF, LVEF ≤35%, sinus rhythm, and resting heart rate ≥70 bpm.
- Patients received either ivabradine or placebo, in addition to standard HF therapy.
- Echocardiographic parameters were analyzed at baseline and after 8 months in 411 patients.
Main Results:
- Ivabradine significantly reduced LV end-systolic volume index (LVESVI) compared to placebo (P<0.001).
- Improvements were observed in LV end-diastolic volume index (P=0.002) and LV ejection fraction (P<0.001) with ivabradine.
- Reduced LVESVI was associated with lower rates of cardiovascular mortality or HF hospitalizations.
Conclusions:
- Ivabradine demonstrates significant efficacy in reversing cardiac remodelling in HF patients.
- The findings support ivabradine as a therapeutic option for managing HF with systolic dysfunction.
- Targeting LV remodelling with ivabradine may improve clinical outcomes in heart failure.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure V: Medical Management
Heart Failure II: Pathophysiology

